{"prompt": "['Product: MK-3475', '7', 'Protocol/Amendment No.: 604-09', '8.12', 'Extent of Exposure', '115', '9.0', 'LABELING, PACKAGING, STORAGE AND RETURN OF CLINICAL', 'SUPPLIES', '115', '9.1', 'Investigational Product', '115', '9.2', 'Packaging and Labeling Information', '116', '9.3', 'Clinical Supplies Disclosure', '116', '9.4', 'Storage and Handling Requirements', '117', '9.5', 'Discard/Destruction/Returns and Reconciliation', '117', '9.6', 'Standard Policies', '117', '10.0', 'ADMINISTRATIVE AND REGULATORY DETAILS', '117', '10.1', 'Confidentiality', '117', '10.1.1 Confidentiality of Data', '117', '10.1.2 Confidentiality of Subject Records', '118', '10.1.3 Confidentiality of Investigator Information', '118', '10.1.4 Confidentiality of IRB/IEC Information', '118', '10.2', 'Compliance with Financial Disclosure Requirements', '119', '10.3', 'Compliance with Law, Audit and Debarment', '119', '10.4', 'Compliance with Trial Registration and Results Posting Requirements', '121', '10.5', 'Quality Management System', '121', '10.6', 'Data Management', '122', '10.7', 'Publications', '122', '11.0', 'LIST OF REFERENCES', '123', '12.0', 'APPENDICES', '135', '12.1', 'Merk Code of Conduct for Clinical Trials', '135', '12.2', 'Collection and Management of Specimens for Future Biomedical', 'Research', '137', '12.3', 'ECOG Performance Status', '141', '12.4', 'Common Terminology Criteria for Adverse Events Version 4.0', '142', '12.5', 'Response Evaluation Criteria in Solid Tumors (RECIST) V1.1 Criteria', 'for Evaluating Response in Solid Tumors', '143', '12.6', 'List of Abbreviations', '144', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '8', 'Protocol/Amendment No.: 604-09', '13.0 SIGNATURES', '148', '13.1', \"Sponsor's Representative\", '148', '13.2', 'Investigator', '148', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '9', 'Protocol/Amendment No.: 604-09', 'LIST OF TABLES', 'Table 1', 'Adequate Organ Function Lab Values', '34', 'Table 2', 'Trial Treatments', '38', 'Table 3', 'Dose Modifications for Study Drugs', '40', 'Table 4', 'Dose Modification and Toxicity Management Guidelines for Immune-', 'Related AEs Associated With Pembrolizumab', '42', 'Table 5', 'Pembrolizumab Infusion Reaction Dose Modification and Treatment', 'Guidelines', '46', 'Table 6', 'Recommended Chemotherapy Dose Modifications for Hematological', 'Toxicity', '49', 'Table 7', 'Recommended Chemotherapy Dose Modifications for Non-hematologic', 'Toxicity', '50', 'Table 8', 'Imaging and Treatment After First Radiologic Evidence of Progressive', 'Disease', '82', 'Table 9', 'Clinical Laboratory Tests', '85', 'Table 10', 'Evaluating Adverse Events', '98', 'Table 11', 'Censoring Rules for Primary and Sensitivity Analyses of Progression-free', 'Survival', '106', 'Table 12', 'Censoring Rules for Duration of Response', '107', 'Table 13', 'Efficacy Analysis Methods for Primary and Secondary Efficacy Endpoints 108', 'Table 14', 'Analysis Strategy for Safety Parameters', '109', 'Table 15', 'Efficacy Boundaries and Properties for Progression-free Survival Analyses . 112', 'Table 16', 'Efficacy Boundaries and Properties for Overall Survival Analyses', '113', 'Table 17', 'Possible Alpha-levels and Approximate ORR Difference Required to', 'Demonstrate Efficacy for ORR', '114', 'Table 18', 'Product Descriptions', '116', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}